



# Grant of Options

June 23, 2023 2:46 PM EDT

RNS Number : 7871D  
MaxCyte, Inc.  
23 June 2023



**MaxCyte, Inc.**  
("MaxCyte" or the "Company")

## Grant of Options

**ROCKVILLE, MD, June 23, 2023:** MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, announces that on 22 June 2023, a total of 400,000 options of common stock in the Company ("Common Stock") were granted to PDMRs who are non-executive directors of the Company. These annual option grants were made pursuant to the Company's Equity Grant Policy for non-executive directors ("Option Grants"). Details of the Option Grants are given below:

<b>Option Grants to PDMRs</b>	
Al-Wakeel, Yasir	50,000
Brooke, Will	50,000
Balthrop, Patrick	50,000
Douglas, Richard	50,000
Erck, Stanley	50,000
Hemrajani, Rekha	50,000
Johnston, John	50,000
Mandell, Art	50,000
<b>Total</b>	<b>400,000</b>

Option Grants for non-executive directors fully vest at the end of twelve (12) months after date of grant. (1 year cliff until fully vested).

The Options Grants have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 22 June 2023, of \$4.57 on the United States Nasdaq Stock Exchange.

### About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our

ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at [maxcyte.com](http://maxcyte.com) and follow us on Twitter and LinkedIn.

**MaxCyte Contacts:**

**US IR Adviser**

**Gilmartin Group**  
David Deuchler, CFA

+1 415-937-5400  
[ir@maxcyte.com](mailto:ir@maxcyte.com)

**Nominated Adviser and Joint**

**Corporate Broker**

Panmure Gordon  
Emma Earl / Freddy Crossley  
Corporate Broking  
Rupert Dearden

+44 (0)20 7886 2500

**UK IR Adviser**

**Consilium Strategic  
Communications**  
Mary-Jane Elliott  
Chris Welsh

+44 (0)203 709 5700  
[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

**NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM**

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	<ul style="list-style-type: none"> <li>a) Yasir Al-Wakeel</li> <li>b) Will Brooke</li> <li>c) Patrick Balthrop</li> <li>d) Richard Douglas</li> <li>e) Stanley Erck</li> <li>f) Rekha Hemrajani</li> <li>g) John Johnston</li> <li>h) Art Mandell</li> </ul>
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	<ul style="list-style-type: none"> <li>a) Non-Executive Director</li> <li>b) Non-Executive Director</li> <li>c) Non-Executive Director</li> <li>d) Non-Executive Chairman</li> <li>e) Non-Executive Director</li> <li>f) Non-Executive Director</li> <li>g) Non-Executive Director</li> <li>h) Non-Executive Director</li> </ul>
b)	Initial notification /Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	MaxCyte Inc.

b)	LEI	54930053YHXULRFCU991																		
4	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>																			
a)	Description of the financial instrument, type of instrument  Identification code	Common Stock of \$0.01 each  US57777K1060																		
b)	Nature of the transaction	Grant of options of common stock																		
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Exercise Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>a) \$4.57</td> <td>50,000</td> </tr> <tr> <td>b) \$4.57</td> <td>50,000</td> </tr> <tr> <td>c) \$4.57</td> <td>50,000</td> </tr> <tr> <td>d) \$4.57</td> <td>50,000</td> </tr> <tr> <td>e) \$4.57</td> <td>50,000</td> </tr> <tr> <td>f) \$4.57</td> <td>50,000</td> </tr> <tr> <td>g) \$4.57</td> <td>50,000</td> </tr> <tr> <td>h) \$4.57</td> <td>50,000</td> </tr> </tbody> </table>	Exercise Price(s)	Volume(s)	a) \$4.57	50,000	b) \$4.57	50,000	c) \$4.57	50,000	d) \$4.57	50,000	e) \$4.57	50,000	f) \$4.57	50,000	g) \$4.57	50,000	h) \$4.57	50,000
Exercise Price(s)	Volume(s)																			
a) \$4.57	50,000																			
b) \$4.57	50,000																			
c) \$4.57	50,000																			
d) \$4.57	50,000																			
e) \$4.57	50,000																			
f) \$4.57	50,000																			
g) \$4.57	50,000																			
h) \$4.57	50,000																			
d)	Aggregated information  - Aggregated volume  - Price	400,000  \$4.57																		
e)	Date of the transaction	22 June 2023																		
f)	Place of the transaction	US Stock Exchange, Nasdaq																		

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFJMITMTITBJJ